Cargando…

Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer

Indoleamine 2,3-dioxygenase (IDO) has recently been proposed to account for tumor-induced immunosuppression by influencing the conversion of tryptophan (Trp) into kynurenine (Kyn). The objective of our study was to correlate IDO activity with disease outcome in non-small cell lung cancer (NSCLC) pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Creelan, Ben C., Antonia, Scott, Bepler, Gerold, Garrett, Timothy J., Simon, George R., Soliman, Hatem H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661168/
https://www.ncbi.nlm.nih.gov/pubmed/23802083
http://dx.doi.org/10.4161/onci.23428
_version_ 1782270640016850944
author Creelan, Ben C.
Antonia, Scott
Bepler, Gerold
Garrett, Timothy J.
Simon, George R.
Soliman, Hatem H.
author_facet Creelan, Ben C.
Antonia, Scott
Bepler, Gerold
Garrett, Timothy J.
Simon, George R.
Soliman, Hatem H.
author_sort Creelan, Ben C.
collection PubMed
description Indoleamine 2,3-dioxygenase (IDO) has recently been proposed to account for tumor-induced immunosuppression by influencing the conversion of tryptophan (Trp) into kynurenine (Kyn). The objective of our study was to correlate IDO activity with disease outcome in non-small cell lung cancer (NSCLC) patients treated with multimodal combination therapy. In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. The mean plasma Kyn/Trp ratio was used as a surrogate indicator of IDO activity. The 33 participants were distributed as follows: 15 females, 18 males; median age = 62; median overall survival (OS) = 22.4 (95% CI 19.3–25.1) months; median progression-free survival (PFS) = 11.5 (95% CI 6.7–16.3) months. The mean Kyn/Trp ratio at baseline (4.5 ± 2.8) was higher than that of healthy controls (2.9 ± 1.9, p = 0.03) and increased after induction therapy (5.2 ± 3.2, p = 0.08) and chemoradiation (5.8 ± 3.9, p = 0.01). The post-treatment Kyn/Trp ratio and radiologic responses were not significantly associated at any time point. No significant correlation was found between baseline Kyn/Trp ratios and OS (HR = 1.1, 95% CI 0.45–2.5) or PFS (HR = 0.74, 95% CI 0.30–1.82). A post-induction chemotherapy increase in IDO activity portended worse OS (HR = 0.43, 95% CI 0.19–0.95, p = 0.037) and PFS (HR = 0.47, 95% CI 0.22–1.0, p = 0.055). This observed increase in IDO transcription may be a means for tumors to evade immunosurveillance.
format Online
Article
Text
id pubmed-3661168
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36611682013-06-25 Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer Creelan, Ben C. Antonia, Scott Bepler, Gerold Garrett, Timothy J. Simon, George R. Soliman, Hatem H. Oncoimmunology Original Research Indoleamine 2,3-dioxygenase (IDO) has recently been proposed to account for tumor-induced immunosuppression by influencing the conversion of tryptophan (Trp) into kynurenine (Kyn). The objective of our study was to correlate IDO activity with disease outcome in non-small cell lung cancer (NSCLC) patients treated with multimodal combination therapy. In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. The mean plasma Kyn/Trp ratio was used as a surrogate indicator of IDO activity. The 33 participants were distributed as follows: 15 females, 18 males; median age = 62; median overall survival (OS) = 22.4 (95% CI 19.3–25.1) months; median progression-free survival (PFS) = 11.5 (95% CI 6.7–16.3) months. The mean Kyn/Trp ratio at baseline (4.5 ± 2.8) was higher than that of healthy controls (2.9 ± 1.9, p = 0.03) and increased after induction therapy (5.2 ± 3.2, p = 0.08) and chemoradiation (5.8 ± 3.9, p = 0.01). The post-treatment Kyn/Trp ratio and radiologic responses were not significantly associated at any time point. No significant correlation was found between baseline Kyn/Trp ratios and OS (HR = 1.1, 95% CI 0.45–2.5) or PFS (HR = 0.74, 95% CI 0.30–1.82). A post-induction chemotherapy increase in IDO activity portended worse OS (HR = 0.43, 95% CI 0.19–0.95, p = 0.037) and PFS (HR = 0.47, 95% CI 0.22–1.0, p = 0.055). This observed increase in IDO transcription may be a means for tumors to evade immunosurveillance. Landes Bioscience 2013-03-01 2013-03-01 /pmc/articles/PMC3661168/ /pubmed/23802083 http://dx.doi.org/10.4161/onci.23428 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Original Research
Creelan, Ben C.
Antonia, Scott
Bepler, Gerold
Garrett, Timothy J.
Simon, George R.
Soliman, Hatem H.
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
title Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
title_full Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
title_fullStr Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
title_full_unstemmed Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
title_short Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
title_sort indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage iii non-small cell lung cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661168/
https://www.ncbi.nlm.nih.gov/pubmed/23802083
http://dx.doi.org/10.4161/onci.23428
work_keys_str_mv AT creelanbenc indoleamine23dioxygenaseactivityandclinicaloutcomefollowinginductionchemotherapyandconcurrentchemoradiationinstageiiinonsmallcelllungcancer
AT antoniascott indoleamine23dioxygenaseactivityandclinicaloutcomefollowinginductionchemotherapyandconcurrentchemoradiationinstageiiinonsmallcelllungcancer
AT beplergerold indoleamine23dioxygenaseactivityandclinicaloutcomefollowinginductionchemotherapyandconcurrentchemoradiationinstageiiinonsmallcelllungcancer
AT garretttimothyj indoleamine23dioxygenaseactivityandclinicaloutcomefollowinginductionchemotherapyandconcurrentchemoradiationinstageiiinonsmallcelllungcancer
AT simongeorger indoleamine23dioxygenaseactivityandclinicaloutcomefollowinginductionchemotherapyandconcurrentchemoradiationinstageiiinonsmallcelllungcancer
AT solimanhatemh indoleamine23dioxygenaseactivityandclinicaloutcomefollowinginductionchemotherapyandconcurrentchemoradiationinstageiiinonsmallcelllungcancer